<DOC>
	<DOCNO>NCT01586533</DOCNO>
	<brief_summary>This double-blind , randomize , comparator-controlled Phase II study design establish safety efficacy Zoenasa Rectal Gel compare mesalamine enema subject left-sided ulcerative colitis , measure modify ulcerative colitis disease activity index ( UCDAI ) , 6 week treatment . In study , two cohort subject receive either Zoenasa-1:4 ( 1.0g NAC ; 4.0g 5-ASA ) investigational drug enema therapy comparator mesalamine enema ( 4.0g 5-ASA ) . The study enroll subject randomize equally 2 cohort . Each cohort enroll approximately 60 subject . The two arm trial enrol concurrently randomize fashion .</brief_summary>
	<brief_title>Study Safety Efficacy Zoenasa® Versus Mesalamine Enema Subjects With Left-Sided Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Male female subject eligible ≥ 18 year age ≤ 64 year . They document history idiopathic ulcerative colitis base endoscopic and/or histologic finding involve left side colon , mild moderate active disease . Eligible subject document history ulcerative colitis , modify UCDAI score 410 , inclusive , Physician 's rating disease score 2 point less ( mild moderate active ulcerative colitis ) , rectal bleeding score 1 ( base subject diary ) , mucosal appearance score ( base endoscopy ) 1 point baseline . Laboratory data : White blood cell count 4.0 12.0 K/mm3 Platelet count : 150 500 K/mm3 Hemoglobin &gt; 10.0 g/dL Total bilirubin &lt; 1.5 mg/dL Aspartate aminotransferase &lt; 100 u/dL Alanine aminotransferase &lt; 100 u/dL Alkaline phosphatase &lt; 250 u/dL Blood urine nitrogen &lt; 40 mg/dL Creatinine &lt; 1.5 mg/dL Satisfies one following : Female subject childbearing potential must negative urine pregnancy test screening ; surgically sterile , postmenopausal , abstinent , patient partner agree use medically appropriate form birth control screen 1 month last dose study medication . Male subject must surgically sterile , abstinent , patient partner compliant contraceptive regimen screen 1 month last dose study medication . They able understand sign write informed consent form , must obtain prior initiation study procedure . They document history proximal universal ulcerative colitis , proctitis active proctitis confine 15cm less anal verge . They demonstrate sign symptom fulminant colitis , bowel stricture , toxic megacolon , anticipate need blood transfusion gastrointestinal bleeding , demonstrate evidence peritonitis . They receive Physician 's rating disease severity part modify UCDAI 3 ( severe disease ) aggregate score 11 great . They show prior documented history evidence high grade dysplasia biopsy endoscopic examination . Their stool contains enteric pathogen Clostridium difficile toxin . They history recurrent Clostridium difficile infection . They prior history biologic therapy within previous 4 year . They receive systemic steroid immunosuppressant within previous 4 week . Treatment last 14 day include antibiotic , antifungal , antiparasitic medication , rectally administer steroid ( e.g . Cortenema® ) mesalamine enema ( Rowasa® ) . Treatment last 7 day include mesalamine ( 5ASA ) via oral administration ( e.g . Asacol® , Lialda® , balsalazide , etc ) . They history cancer ( defined malignancy within 5 year except squamous cell basal cell cancer skin ) , asthma , bronchospasm . Positive pregnancy test lactating subject . There evidence chemical substance abuse . They repeat antiinflammatory drug treatment ( long 3 day dos exceed available without prescription ) within previous 7 day ( exception aspirin dose 325mg/day less prophylaxis cardiac disease ) , initiate new nonsteroidal antiinflammatory ( NSAID ) treatment within last 30 day . They know allergy Nacetylcysteine mesalamine , history serious AEs relate use ( include , limited pancreatitis hepatitis ) . They history failure retain enema . Other clinically significant disease could interfere protocol compliance appear . These would include clinically important hematological , renal , hepatic , metabolic , psychiatric , central nervous system ( CNS ) , pulmonary cardiovascular disease . Use investigational medication within previous 90 day . Any condition study physician judge preclude safe participation study confound evaluation study outcome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>ulcerative colitis</keyword>
	<keyword>UC</keyword>
	<keyword>left-sided ulcerative colitis</keyword>
	<keyword>distal ulcerative colitis</keyword>
	<keyword>Zoenasa</keyword>
	<keyword>mesalamine</keyword>
	<keyword>mesalazine</keyword>
	<keyword>5-ASA</keyword>
	<keyword>5-aminosalicylic acid</keyword>
	<keyword>N-acetylcysteine</keyword>
	<keyword>acetylcysteine</keyword>
	<keyword>NAC</keyword>
	<keyword>enema</keyword>
	<keyword>rectal gel</keyword>
</DOC>